220 related articles for article (PubMed ID: 24815845)
21. Ewing sarcoma of the hand or foot.
Froeb D; Ranft A; Boelling T; Paulussen M; Klco-Brosius S; Jürgens H; Dirksen U
Klin Padiatr; 2012 Oct; 224(6):348-52. PubMed ID: 23143762
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study.
Obata H; Ueda T; Kawai A; Ishii T; Ozaki T; Abe S; Tanaka K; Tsuchiya H; Matsumine A; Yabe H;
Cancer; 2007 Feb; 109(4):767-75. PubMed ID: 17238190
[TBL] [Abstract][Full Text] [Related]
23. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
24. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience.
Milano GM; Cozza R; Ilari I; De Sio L; Boldrini R; Jenkner A; De Ioris M; Inserra A; Dominici C; Donfrancesco A
Cancer; 2006 Apr; 106(8):1838-45. PubMed ID: 16532434
[TBL] [Abstract][Full Text] [Related]
25. Non-Metastatic Pelvic Ewing's Sarcoma : oncologic outcomes and evaluation of prognostic factors.
Dramis A; Grimer RJ; Malizos K; Tillman RM; Jeys L; Carter LR
Acta Orthop Belg; 2016 Aug; 82(2):216-221. PubMed ID: 27682283
[TBL] [Abstract][Full Text] [Related]
26. Definitive surgery and multiagent systemic therapy for patients with localized Ewing sarcoma family of tumors: local outcome and prognostic factors.
Krasin MJ; Davidoff AM; Rodriguez-Galindo C; Billups CA; Fuller CE; Neel MD; Merchant TE
Cancer; 2005 Jul; 104(2):367-73. PubMed ID: 15948159
[TBL] [Abstract][Full Text] [Related]
27. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies.
Paulussen M; Ahrens S; Burdach S; Craft A; Dockhorn-Dworniczak B; Dunst J; Fröhlich B; Winkelmann W; Zoubek A; Jürgens H
Ann Oncol; 1998 Mar; 9(3):275-81. PubMed ID: 9602261
[TBL] [Abstract][Full Text] [Related]
28. Long-term Outcomes and Complications in Pediatric Ewing Sarcoma.
Hamilton SN; Carlson R; Hasan H; Rassekh SR; Goddard K
Am J Clin Oncol; 2017 Aug; 40(4):423-428. PubMed ID: 25599318
[TBL] [Abstract][Full Text] [Related]
29. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
Van Winkle P; Angiolillo A; Krailo M; Cheung YK; Anderson B; Davenport V; Reaman G; Cairo MS
Pediatr Blood Cancer; 2005 Apr; 44(4):338-47. PubMed ID: 15503297
[TBL] [Abstract][Full Text] [Related]
30. Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow.
Thiel U; Wawer A; von Luettichau I; Bender HU; Blaeschke F; Grunewald TG; Steinborn M; Röper B; Bonig H; Klingebiel T; Bader P; Koscielniak E; Paulussen M; Dirksen U; Juergens H; Kolb HJ; Burdach SE
Oncotarget; 2016 Oct; 7(43):70959-70968. PubMed ID: 27486822
[TBL] [Abstract][Full Text] [Related]
31. Pattern of relapse in 290 patients with nonmetastatic Ewing's sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999.
Bacci G; Longhi A; Ferrari S; Mercuri M; Barbieri E; Bertoni F; Bacchini P; Picci P
Eur J Surg Oncol; 2006 Nov; 32(9):974-9. PubMed ID: 16621429
[TBL] [Abstract][Full Text] [Related]
32. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
[TBL] [Abstract][Full Text] [Related]
33. Survival of patients with Ewing's sarcoma in Yazd-Iran.
Akhavan A; Binesh F; Shamshiri H; Ghanadi F
Asian Pac J Cancer Prev; 2014; 15(12):4861-4. PubMed ID: 24998554
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection.
Pan HY; Morani A; Wang WL; Hess KR; Paulino AC; Ludwig JA; Lin PP; Daw NC; Mahajan A
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):349-57. PubMed ID: 25772182
[TBL] [Abstract][Full Text] [Related]
35. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
[TBL] [Abstract][Full Text] [Related]
36. Non-metastatic Ewing's sarcoma family of tumors of bone in adolescents and adults: prognostic factors and clinical outcome-single institution results.
Oksüz DC; Tural D; Dincbas FÖ; Dervisoglu S; Turna H; Hiz M; Kantarci F; Ceylaner B; Koca S; Mandel NM
Tumori; 2014; 100(4):452-8. PubMed ID: 25296596
[TBL] [Abstract][Full Text] [Related]
37. Multimodality Treatment of Pediatric and Adult Patients With Ewing Sarcoma: A Single-institution Experience.
Diaz-Beveridge R; Lorente D; Torres B; Cañete A; Rodrigo E; Bruixola G; Berlanga P; Reche E; Montalar J; Verdeguer A; Aparicio J
J Pediatr Hematol Oncol; 2015 Jul; 37(5):e278-84. PubMed ID: 25929608
[TBL] [Abstract][Full Text] [Related]
38. Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors.
Krasin MJ; Rodriguez-Galindo C; Billups CA; Davidoff AM; Neel MD; Merchant TE; Kun LE
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):830-8. PubMed ID: 15465200
[TBL] [Abstract][Full Text] [Related]
39. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma.
Burdach S; Jürgens H; Peters C; Nürnberger W; Mauz-Körholz C; Körholz D; Paulussen M; Pape H; Dilloo D; Koscielniak E
J Clin Oncol; 1993 Aug; 11(8):1482-8. PubMed ID: 8101562
[TBL] [Abstract][Full Text] [Related]
40. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
